Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26940090 |
US |
76 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 2 | 26940229 |
US |
9 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 3 | 26940440 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, Product storage issue, |
||||
INSULIN GLARGINE, |
||||
| 4 | 26940459 |
US |
77 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 5 | 26940832 |
US |
35 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 6 | 26940834 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 7 | 26940846 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 8 | 26941122 |
US |
48 | 1 |
Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, |
||||
MEPOLIZUMAB, |
||||
| 9 | 26941222 |
US |
85 | 2 |
Injection site bruising, Injection site erythema, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 10 | 26941332 |
US |
31 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 11 | 26941434 |
US |
||
Injury associated with device, Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 12 | 26941678 |
US |
69 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 13 | 26941680 |
US |
38 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 14 | 26942108 |
US |
49 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 15 | 26942123 |
US |
46 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 16 | 26942156 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 17 | 26942414 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 18 | 26942436 |
US |
58 | 2 |
Exposure via skin contact, Accidental exposure to product, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 19 | 26942472 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 20 | 26942686 |
CA |
54 | |
Ileal stenosis, Abdominal pain upper, Oral herpes, Drug delivery system malfunction, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, AZATHIOPRINE, AZATHIOPRINE, |
||||
| 21 | 26942832 |
US |
18 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 22 | 26942845 |
US |
30 | 1 |
Skin irritation, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 23 | 26942855 |
US |
18 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 24 | 26942870 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 25 | 26942886 |
US |
59 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 26 | 26942968 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 27 | 26943287 |
US |
||
Injury associated with device, Wrong technique in device usage process, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 28 | 26943635 |
US |
84 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 29 | 26944111 |
US |
73 | 2 |
Injection site indentation, Accidental exposure to product, Exposure via skin contact, Injection site haemorrhage, Product communication issue, |
||||
EVOLOCUMAB, |
||||
| 30 | 26944166 |
US |
31 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 31 | 26944171 |
US |
46 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 32 | 26944172 |
US |
36 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 33 | 26944179 |
US |
44 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 34 | 26944190 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 35 | 26944574 |
US |
1 | |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, Device malfunction, |
||||
DUPILUMAB, |
||||
| 36 | 26944589 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 37 | 26944590 |
US |
48 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 38 | 26944591 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 39 | 26944977 |
US |
82 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 40 | 26945070 |
US |
63 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 41 | 26946331 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 42 | 26947516 |
US |
55 | 1 |
Accidental exposure to product, Exposure via skin contact, Product administered at inappropriate site, |
||||
EVOLOCUMAB, |
||||
| 43 | 26934089 |
US |
60 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 44 | 26934290 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 45 | 26934292 |
US |
15 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 46 | 26934305 |
US |
88 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 47 | 26934306 |
US |
14 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 48 | 26934586 |
US |
19 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 49 | 26934597 |
US |
23 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 50 | 26934609 |
US |
7 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 51 | 26934616 |
GB |
58 | |
Uveitis, Device malfunction, Product leakage, Accidental exposure to product, Exposure via skin contact, Drug ineffective, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 52 | 26934732 |
US |
63 | 2 |
Accidental exposure to product, Drug dose omission by device, Exposure via skin contact, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 53 | 26934844 |
US |
69 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 54 | 26934868 |
US |
67 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 55 | 26934871 |
US |
7 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 56 | 26935105 |
US |
68 | 2 |
Cystoid macular oedema, Accidental exposure to product, Exposure via skin contact, Product use issue, |
||||
DUPILUMAB, |
||||
| 57 | 26935120 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 58 | 26935597 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 59 | 26935660 |
US |
2 | |
Pain, Lacrimation increased, Accidental exposure to product, Exposure via skin contact, Circumstance or information capable of leading to medication error, |
||||
LIFITEGRAST, |
||||
| 60 | 26935770 |
US |
75 | 2 |
Disability, Accidental exposure to product, Exposure via skin contact, Product administration error, Product communication issue, Wrong technique in product usage process, Drug dose omission by device, |
||||
DENOSUMAB, |
||||
| 61 | 26935970 |
US |
68 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 62 | 26935983 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 63 | 26935997 |
US |
1 | |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 64 | 26936027 |
US |
58 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, |
||||
ERENUMAB-AOOE, |
||||
| 65 | 26936204 |
US |
60 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 66 | 26936330 |
US |
81 | 1 |
Cough, Productive cough, Dyspnoea, Skin discolouration, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 67 | 26936357 |
US |
72 | 1 |
Product communication issue, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 68 | 26936367 |
US |
35 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 69 | 26936621 |
US |
61 | |
Device leakage, Product dose omission issue, Exposure via skin contact, |
||||
GUSELKUMAB, |
||||
| 70 | 26936704 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 71 | 26936756 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 72 | 26936759 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 73 | 26937106 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 74 | 26937190 |
US |
69 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 75 | 26937494 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 76 | 26937536 |
US |
74 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 77 | 26937928 |
US |
22 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 78 | 26938325 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 79 | 26938349 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 80 | 26938364 |
US |
60 | 2 |
Exposure via skin contact, Wrong technique in device usage process, |
||||
BELIMUMAB, |
||||
| 81 | 26938564 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 82 | 26939888 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 83 | 26939967 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 84 | 26939993 |
EU |
3 | 2 |
Precocious puberty, Epiphyses premature fusion, Accidental exposure to product by child, Exposure via skin contact, |
||||
ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, |
||||
| 85 | 26931193 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ASCORBIC ACID, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, BIOTIN, CARBIDOPA AND LEVODOPA, CETIRIZINE HCL, CETIRIZINE, CERTOLIZUMAB PEGOL, CLINDAMYCIN HYDROCHLORIDE, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, IPRATROPIUM BROMIDE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PREDNISONE, ACETAMINOPHEN, DIPHENHYDRAMINE HYDROCHLORIDE, ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE, ERGOCALCIFEROL, CETIRIZINE HYDROCHLORIDE, |
||||
| 86 | 26932109 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 87 | 26932243 |
US |
36 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 88 | 26932253 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 89 | 26932301 |
US |
75 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 90 | 26932303 |
US |
68 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 91 | 26932306 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 92 | 26932310 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 93 | 26932312 |
US |
53 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 94 | 26932328 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, MEPOLIZUMAB, |
||||
| 95 | 26932378 |
US |
24 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 96 | 26932413 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 97 | 26932419 |
US |
73 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 98 | 26932580 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 99 | 26932581 |
US |
45 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 100 | 26932601 |
US |
6 | 1 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30